Skip to main content
S&P 5007,688.62+1.58%DOW53,356.12+3.03%NASDAQ25,736.51+1.44%BTC$80,787.00+5.07%ETH$2,431.65+7.47%GOLD$4,134.30+1.51%OIL$87.17-1.08%
Smart Investors Daily
SID Premium
Biofrontera Inc. Warrants logo

NASDAQ · BFRIW

Biofrontera Inc. Warrants

Healthcare · Drug Manufacturers - Specialty & Generic

$0.00

Up+$0.00 (+0.00%)

Updated Nov 5, 2026, 9:08 AM

SID Score

2.3/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
815.95K
P/E ratio
-0.45
Dividend yield
0.00%
52-week range
$0.00 – $0.28
Volume
37.97K
Avg. volume
8.86K

Price performance · BFRIW

BFRIW price history

1M range · 14 trading sessions · Daily adjusted prices

Prices through Oct 30, 2026

BFRIW closed at $0.00 after 14 trading sessions, down 87.16% for the selected period.

Last close
$0.00
Period change
-87.16%
Period low
$0.00
Period high
$0.01
Daily close
View OHLC price history
BFRIW OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 30, 2026$0.0014$0.0014$0.0014$0.001437.97K
Oct 29, 2026$0.002$0.002$0.0014$0.00141.2K
Oct 28, 2026$0.0014$0.0014$0.0014$0.0014185
Oct 27, 2026$0.0016$0.002$0.0013$0.001421.3K
Oct 26, 2026$0.0016$0.0026$0.0015$0.002658K
Oct 23, 2026$0.0051$0.0052$0.005$0.00511.86K
Oct 22, 2026$0.005$0.005$0.005$0.00510.08K
Oct 21, 2026$0.005$0.0052$0.005$0.00525.43K
Oct 20, 2026$0.0052$0.0052$0.005$0.005213.51K
Oct 19, 2026$0.0061$0.0061$0.0052$0.0052982
Oct 15, 2026$0.006$0.006$0.005$0.005219.24K
Oct 9, 2026$0.008$0.008$0.0056$0.00565.29K
Oct 8, 2026$0.009$0.009$0.007$0.0072.01K
Oct 7, 2026$0.0052$0.0109$0.0052$0.0109778

Latest BFRIW news

The latest Smart Investors Daily articles mentioning BFRIW.

Stock researchCompany · Overview

BFRIW research

Overview

Company profile and research snapshot.

Company profile

Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy. The Company's licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (together, the RhodoLED Lamps), are used for the treatment of actinic keratoses (AKs), which are pre-cancerous skin lesions.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 8, 2026

Biofrontera Submits Supplemental New Drug Application to FDA to Expand Ameluz® Red Light PDT to Actinic Keratoses on the Full Body

Submission seeks to extend the Ameluz® label beyond the face and scalp to treatment fields of up to approximately 240 cm² on the rest of the body, with an adjusted illumination protocol WOBURN, Mass., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT) in dermatology, today announced that it has submitted a supplemental New Drug Applicati

Yahoo · Sep 14, 2026

Biofrontera Announces FDA Approval of Ameluz® Red Light PDT for the Treatment of Superficial Basal Cell Carcinoma

Ameluz used in conjunction with the RhodoLED lamp becomes the first and only photodynamic therapy approved in the United States to treat a skin cancer, creating an additional growth opportunity for Biofrontera’s photodynamic therapy platform WOBURN, Mass., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ: BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT) in dermatology, today announce

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By